Pauley v. Bayer Corporation et al
Nova Scotia Supreme Court File: Hfx No. 330493
On June 10, 2010, Wagners Law Firm filed a proposed common law class proceeding on behalf of all Canadian residents who have been prescribed the birth control medication known as Yasmin and Yaz.
Yasmin & Yaz (which are manufactured by Bayer AG and its subsidiaries) are prescription birth control medications which unlike other contraceptives on the market contain a “fourth generation” progestin called drospirenone. Yasmin and Yaz were approved for sale in Canada in 2004 and 2008 respectively. During the brief time that Yasmin and Yaz have been approved for sale in Canada, a total of over 120 reports of injury and death have been submitted to Health Canada in association with the Defendants’ products. Among the more common complaints are cases of deep vein thrombosis, blood clots, strokes, heart attacks, and pulmonary embolisms.
Numerous studies and papers have been published in reputable journals concerning the safety of both Yasmin and Yaz.
In April 2002, the British Medical Journal reported that the Dutch College of Medical Practitioners recommended that older, second generation birth control pills be prescribed instead of Yasmin as a result of 40 cases of venous thrombosis among women who had taken Yasmin.
In February 2003, a paper entitled Thromboembolism Associated with the New Contraceptive Yasmin was published in the British Medical Journal detailing a Netherlands Pharmacovigilance Centre report of five additional reports of thromboembolism, including two deaths, where Yasmin was suspected to be the cause.
More recently, in August 2009, the British Medical Journal published the results of a national follow-up study which concluded the oral contraceptives containing drospirenone, such as Yasmin and Yaz, are associated with a significantly higher risk of venous thromboembolism than other oral contraceptives.
Patients taking Yasmin or Yaz should consult with their physician should they have any concerns with regard to continuing or discontinuing their use of Yasmin or Yaz.
If you or a loved have experienced deep vein thrombosis, blood clots, stroke, heart attacks, or pulmonary embolisms, please contact the offices of Wagners Law Firm at (902) 425-7330 or 1-800-INJURY4 (1-800-465-8794) to be included as a proposed class member in the lawsuit.
Wagners is presently accepting enquiries from residents of Canada who have suffered deep vein thrombosis, blood clots, stroke, heart attacks, pulmonary embolisms and/or other adverse effects associated with the use of Yasmin or Yaz.
If you, or a member of your family, have taken Yasmin or Yaz and serious side effects have resulted, you may be eligible to be included as a Class Member in our proposed class action lawsuit.
To sign up and determine if you qualify, please fill out this registration form:
Updates & Latest Developments
Update – August 22, 2014
We understand that Counsel in other jurisdictions across Canada are in advanced stages concerning their respective class actions concerning Yasmin/Yaz birth control medication.
We have had brief contact with Counsel in Ontario concerning the progress of the case.
Update – January 27, 2011
Wagners commenced a proposed class proceeding on behalf of individuals affected by Yasmin and Yaz medication on June 10, 2010. The Notice of Action and Statement of Claim filed by Wagners Law Firm may be viewed under the Court Documents tab.
Update – January 28, 2016
Wagners are now working cooperatively with a law firm in Ontario to further the claims of those affected by the birth control medication Yasmin or Yaz.
Update – March 10, 2015
We have received notice that dates in April 2015 have been scheduled in Saskatchewan for the hearing of the Plaintiffs’ motion for certification.